Apheresis Equipment Market By Product Type (Plasma Separators, Platelet Separators, Leukocyte Reduction Filters, Blood Cell Separators), By Technology (Centrifugation {Continuous Flow Centrifugation, Intermittent Flow Centrifugation}, Membrane Filtration), By Procedure Type (Plasmapheresis, Plateletpheresis, Leukapheresis, Erythrocytapheresis, Photopheresis, LDL Apheresis, Others), By Application (Neurology, Hematology, Oncology, Renal Disorders, Autoimmune Disorders, Others), By End-user (Hospitals & Clinics, Research & Academic Institutes, Rehabilitation Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles, And Market Forecast, 2025 – 2035

---

Industry Outlook

The Apheresis Equipment market accounted for USD 3.28 Billion in 2024 and is expected to reach USD 8.72 Billion by 2035, growing at a CAGR of around 9.30% between 2025 and 2035. The Apheresis Equipment Market primarily examines medical devices that separate blood elements for treatment purposes or accidental donation. Blood apheresis devices separate various elements from the whole blood before returning the rest to patients or donors. The therapeutic method of apheresis finds extensive application throughout the medical treatment of autoimmune diseases and blood disorders and blood banking activities. Healthcare efficiencies and patient results have improved through automation systems linked with artificial intelligence technology. The market experiences growth through the increasing need for plasma therapy products and the rising number of patients with chronic diseases. The market advancement is intensified by the rising adoption of apheresis procedures in regenerative medicine alongside cellular therapy approaches. The market growth faces obstacles from expensive equipment investments alongside regulatory limitations.

Report Scope:

Market Dynamics

Growing Demand for Plasma-Derived Therapies Due to Rising Cases of Autoimmune Diseases and Blood Disorders

The Apheresis Equipment Market shows major expansion because plasma-derived therapies depend on apheresis equipment to treat three critical disorders, consisting of autoimmune diseases, primary immunodeficiency disorders, and hemophilia. A report shows that hemophilia affects 1 of 5,000 male births globally, thus resulting in regular plasma-based therapeutic needs. The growing number of Guillain-Barré syndrome, myasthenia gravis, and thrombocytopenia cases drives the need for therapeutic apheresis treatments. Plasma exchange has emerged as standard medical therapy for neurological as well as hematological conditions, which leads to better clinical results for patients. The market expansion is driven by the increasing medical use of plasma therapeutic interventions for severe infections such as sepsis. Market demand for plasma-derived products will increase dramatically because of population aging and rising disease prevalence across the world.

Programs supported by governments through funding of blood plasma collection centers continue to increase, with positive effects on apheresis procedure accessibility. AI technologies combined with automation in apheresis devices lead to improved precision, which generates both shorter procedures and fewer adverse effects. The Department of Industry is accelerating the pharmaceutical sphere through partnership development between biopharmaceutical corporations and blood banks to optimize plasma obtainment, along with processing techniques. The rising market demand motivates companies to create low-cost advanced apheresis devices that drive industrial growth.

Increasing Blood Donations and the Growing Need for Safe Blood Component Separation in Transfusion Medicine

The Apheresis Equipment Market maintains a growing demand for the clinical need for blood transfusions in trauma cases, surgery, and chronic disease management requires innovative methods to separate blood components. Yearly blood donation collections worldwide amount to over 118.5 million based on WHO reports, while high-income countries maintain a donation share of 42%. The apheresis process allows quantitative separation of platelets, plasma, and red blood cells from donor blood, thus maximizing blood resource efficiency. The successful treatment of conditions such as sickle cell disease as well as leukemia depends heavily on specific transfusions, which improve their therapeutic outcomes. The increasing complexity of surgical operations, including organ transplants and cardiovascular procedures, has caused blood component quality to become an essential medical necessity. The healthcare industry dedicated more resources to next-generation apheresis devices following its increased focus on infection control as well as safe transfusions.

Automated apheresis systems create safer donation environments through enhanced protection of donors while simultaneously reducing operational risks and providing specific blood part extraction. Various public initiatives backed by governmental organizations and nonprofit groups work to create awareness regarding voluntary blood donation to support worldwide blood banks. The rising use of apheresis technology for infectious disease treatment using convalescent plasma has driven its market demand higher. Hospitals can now perform urgent transfusion procedures because point-of-care apheresis systems are becoming more integrated into medical facilities. The apheresis equipment market expands with these concurrent factors to consolidate its position in modern transfusion medicine practice.

High Cost of Apheresis Equipment and Limited Accessibility in Low-Income Countries

The exorbitant price of apheresis equipment restricts its widespread use because it makes the technology inaccessible to resource-constrained locations. The capital needed to acquire modern apheresis equipment extends from thirty thousand dollars up to one hundred and fifty thousand dollars, which exceeds the purchasing capabilities of robust medical centers or blood banks. Medical institutions experience added financial stress due to both expensive maintenance costs and operational costs and operating expenses. The implementation of apheresis procedures faces hurdles because LMICs have weak healthcare systems combined with funding shortages. The insufficient number of appropriately trained professionals to operate and manage these machines impacts both efficiency in procedures and safety for patients.

The financial reimbursement programs for apheresis care differ across geographical areas due to inconsistent healthcare system coverage. The increasing price volatility in raw materials results in higher equipment production expenses, thus affecting the final pricing structure. Developing nations face difficulties acquiring state-of-the-art apheresis devices because they need to depend on traditional blood-separation approaches in their blood collection centers. The lack of public knowledge about apheresis benefits diminishes the number of patients who choose this procedure. Healthcare providers make cost-efficient alternatives their main choice, thereby reducing the potential growth of the apheresis equipment market. The promotion work of international organizations meets resistance from limited funding, which delays broad-scale component separation and blood donation initiatives. Underprivileged regions will maintain difficulties in apheresis adoption because of missing targeted governmental initiatives and funding assistance.

Rising Adoption of Apheresis in Regenerative Medicine and Stem Cell Therapy Advancements

The Apheresis Equipment Market presents favorable growth potential due to the expanding realm of regenerative medicine, together with stem cell therapy, opening up multiple prospects within the apheresis equipment market. Approximately 2 million Americans per year need stem cell apheresis procedures to obtain hematopoietic stem cells that treat their leukemia, lymphoma, and immune system disorders. Selective stem cell extraction through advanced apheresis methods improves both transplant outcome success and donor blood safety after procedures.

Cancer, together with the rise of autoimmune disorders, has pushed the market to require efficient apheresis systems that support stem cell-based therapeutic applications. The expansion of the apheresis market derives from developments in cord blood banking alongside personalized medicine because cell extraction requires apheresis technology. The market growth for cell-based therapies by biopharmaceutical entities demands advanced blood component separating technologies of high quality.

The integration between apheresis equipment and regenerative medicine yields improved benefits through government-sponsored research initiatives and funding programs. The development of CRISPR gene-editing tools and other similar technologies has intensified the necessity for accurate stem cell procurement techniques and handling methods. Apheresis procedures represent an invasive alternative to bone marrow extraction that allows practitioners to reach patients more conveniently while remaining friendly to their needs. Medical research institutions join forces with apheresis equipment manufacturers to develop new technologies. Close-to-term predictions indicate that apheresis technology will play a larger role in cell-based treatments and simultaneously create new revenue opportunities for pharmaceutical companies. Next-generation regenerative medicine solutions get essential support from advanced apheresis equipment technology.

Expanding Role of Therapeutic Apheresis in Neurological and Autoimmune Disease Management

The Apheresis Equipment Market demonstrates growth through the therapeutic use of apheresis and continues to expand in neurological and autoimmune disorders, creating fresh market prospective opportunities. TPE functions as the only proven lifesaving treatment that benefits patients affected by multiple sclerosis, Guillain-Barré syndrome, and myasthenia gravis. Apheresis treatments are gaining popularity because autoimmune disease numbers keep rising to affect about 4% of the worldwide population. Plasma exchange provides a method to remove pathogenic antibodies together with inflammatory mediators to enhance disease management results. Research conducted on clinical patients demonstrates that TPE treatment results in substantial improvement of recovery outcomes for individuals experiencing major neurological disabilities.

Information about therapeutic apheresis continues to increase, so more hospitals are adopting these therapies for patient treatment. Insurance providers are expanding their coverage of apheresis-based therapies, which increases patient opportunities to receive advanced medical procedures. The development of immunotherapy and monoclonal antibodies through research increases the significance of apheresis in precision medicine. Mobile apheresis units have expanded to enhance specialized medical procedures in remote areas. The investment increase in biopharmaceutical research has spurred the market adoption of treatments based on apheresis methods. The market will witness substantial expansion because regulatory bodies continue issuing authorization for innovative apheresis procedures.

Industry Experts Opinion

"Our dedication to apheresis technology innovation seeks to improve patient outcomes and expedite therapeutic processes globally. At Haemonetics, we consistently make investments in cutting-edge blood management systems that enhance patient and healthcare provider accessibility, safety, and efficiency. We are influencing the future of blood and plasma collection by combining state-of-the-art automation, data analytics, and AI-driven technologies, guaranteeing that life-saving treatments reach those in need more precisely and consistently.”

• Chris Simon, CEO of Haemonetics Corporation

Segment Analysis

Based on Assessment Type, the Apheresis Equipment Market is classified as plasma separators, platelet separators, leukocyte reduction filters, and blood cell separators. The Blood Cell Separators segment dominates the market because they find broad application in blood banking operations, therapeutic apheresis procedures, and cellular therapy applications. The separation of blood elements functions as a fundamental process through blood cell separators, which enables targeted transfusion practices and healthcare treatments. Hematological disorders, autoimmune conditions, and cancer-related diseases have pushed up the need for blood cell separation procedures because of their increased prevalence in patient populations. The World Health Organization reports that 118.5 million blood donations take place globally annually, and this sector requires improved methods of blood component separation. Modern automated apheresis technological developments have led to safer blood collection equipment that decreases procedural times while making donors more comfortable. The market growth benefits from the rising use of blood cell separators, which enable stem cell collection applications for regenerative medicine and bone marrow transplants.

Based on Application, the Apheresis Equipment Market is classified into neurology, hematology, oncology, renal disorders, autoimmune disorders, and others. Hematology leads the market because blood disorders occur at high rates, and transfusion therapy requirements keep increasing. Patients affected by leukemia, along with sickle cell anemia, hemophilia, and thrombocytopenia, require repeated apheresis treatments to manage their symptoms while improving treatment results. Apheresis techniques in hematology have experienced powerful demand growth since the number of bone marrow and stem cell transplants continues to rise. The growth of the elderly population, together with increasing blood donation program awareness, drives hospitals and blood banks to expand their apheresis services in hematology. Market growth is supported by expanding advancements in platelet-rich plasma (PRP) treatments. Public healthcare systems, along with government departments, support blood bank modernization through investments that drive more institutions to adopt specialized apheresis devices for hematology needs. Automated blood separation technologies present two benefits procedural safety improvement and efficiency enhancement, which increases accessibility to hematology-based apheresis services.

Regional Analysis

The North American region leads the Apheresis Equipment Market because of its advanced medical structure and elevated blood donation frequency, coupled with rising plasma-based pharmaceutical requirements. The United States leads the market share because it has both important market participants and established blood banks in the country. The market growth benefits from increasing occurrences of autoimmune diseases in combination with blood diseases such as leukemia and thrombocytopenia. Strong industry growth benefits from governmental programs backing plasma collection centers as well as payment policies that support apheresis treatments.

Academic and biopharmaceutical institutions have expanded their use of apheresis systems because of rising research in cell therapy and regenerative medicine. The development of automated systems and artificial intelligence brings improvements to both efficiency and safety when separating blood components. More healthcare providers recognize therapeutic apheresis capability for neurological and cardiovascular conditions, which has stimulated its clinical use range. New apheresis-based therapies approved by the U.S. FDA maintain steady growth in the industry. The Canadian government backs blood donation drives, and its biotechnology sectors expand while making substantial contributions to market development. According to market analysts, North America will securely hold its position as the leading market sector for apheresis equipment worldwide.

The Asia-Pacific is the fastest-growing region in the Apheresis Equipment Market because the region experiences population growth increases along with rising blood disorder cases and improving medical facilities in the area. The blood collection and transfusion enterprise of China, India, and Japan is led by investment to fulfill expanding medical requirements. Health practitioners adopt therapeutic apheresis procedures because of the growing rates of hematological diseases and neurological disorders. Market potential in Asia-Pacific is rising because of quick developments in biopharmaceutical research and regenerative medicine applications. Government-backed blood donation awareness programs, together with the installation of contemporary blood banks, accelerate market expansion. The medical tourism industry of Thailand and Singapore, along with other countries, is driving up demand for state-of-the-art apheresis procedures. The global manufacturing industry advances its Asia-Pacific market presence by establishing strategic agreements with healthcare providers across the region. Developing nations gain better access to apheresis technologies because of rising health costs and equipment technology improvements. The growing attention to personalized medicine, along with cell-based therapies, creates a positive market expansion outlook throughout the Asia-Pacific region.

Competitive Landscape

The Apheresis Equipment Market is a highly competitive market having major participants such as Terumo BCT, Haemonetics Corporation, Fresenius Kabi AG, Asahi Kasei Medical Co., Ltd., and Baxter, which focus on product development together with cooperative alliances and international market expansion to boost their market presence. Companion businesses invest resources into automated equipment artificial intelligence, and machine learning systems for improving the efficiency and safety margins of apheresis procedures. The marketplace includes an upward trend of business consolidation through acquisition deals between companies that both enhance distribution systems and widen product lines.

Manufacturers expand blood component collection efficiency through partnerships between blood banks hospitals, and biopharmaceutical firms because plasma-derived therapy demands are growing. The enhancement of blood donation programs through government funding, together with increased medical facility development in developing nations, continues to shape market conditions. Next-generation apheresis devices are the focus of current R&D efforts because researchers aim to create systems with shortened procedures that yield superior patient results. Companies operating in this field focus on implementing cost-efficient measures to widen apheresis equipment distribution throughout regions with limited economic resources.

The market leaders, Terumo BCT and Haemonetics Corporation are at the forefront of the Apheresis Equipment Market. Terumo BCT implements automated apheresis systems to boost donor and patient outcomes through better efficiency and quality donor and patient experiences. Terumo BCT has achieved worldwide market development through collaborations with blood banks alongside healthcare organizations for plasma collection expansion. Innovation through AI enables the company to optimize blood separation and filtration processes, which results in higher safety, together with improved efficacy. Haemonetics conducted a global expansion move in 2023 when it purchased OpSens Medical to strengthen blood management technology capabilities. The company devotes its resources to AI predictive analytics for optimizing apheresis procedures to achieve better patient outcomes. The company pursues hospital and research institution partnerships to advance innovation in therapeutic apheresis while developing transfusion medicine.

Apheresis Equipment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In March 2024, the company Haemonetics Corporation made a definitive acquisition of the medical manufacturer Attune Medical to gain the FDA-cleared ensoETM® esophageal cooling device. The acquisition focused on raising temperature management during RF cardiac ablation procedures.
• In August 2023, under a supply and development agreement, Fresenius Kabi AG teamed up with Lupagen Inc. for the development of technologies that would enable bedside delivery of cell & gene therapies.

Frequently Asked Questions (FAQs)